There are 3161 resources available
1790P - Phase II data of lurbinectedin (LUR) and irinotecan (IRI) in relapsed small cell lung cancer (SCLC) patients (pts) with chemotherapy-free interval (CTFI)>30 days (d)
Presenter: Jon Zugazagoitia
Session: Poster session 07
1792P - Molecular characterization from IMfirst: Atezolizumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) in Spain
Presenter: Manuel Cobo Dols
Session: Poster session 07
1793P - Treatment and outcomes of limited disease small cell lung cancer (LD-SCLC) in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1794P - Deciphering ERBB2-driven mechanisms that regulate tumor immune evasion and metastasis in SCLC
Presenter: Lydia Meder
Session: Poster session 07
1795P - Consolidation serplulimab following concurrent hypofractionated chemoradiotherapy for limited-stage SCLC: Preliminary analysis of phase II ASTRUM-LC01 study
Presenter: Yuqi Wu
Session: Poster session 07
1796P - Smoking-related genomic mutation patterns in patients with small cell lung cancer treated in ASTRUM-005 study
Presenter: Ying Cheng
Session: Poster session 07
1798P - Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1799P - Efficacy and safety of integrating consolidative thoracic radiotherapy with immunochemotherapy in ES-SCLC: A real-world retrospective analysis
Presenter: Qi Zhang
Session: Poster session 07